Publications by authors named "K Adekola"
Article Synopsis
- The treatment options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) have expanded with new advancements.
- The NCCN Guidelines offer a structured approach for diagnosing, treating, and evaluating responses in patients with WM/LPL.
- These guidelines apply to both newly diagnosed and previously treated individuals, ensuring effective follow-up care.
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
December 2023
Article Synopsis
- - The treatment landscape for relapsed/refractory multiple myeloma has expanded significantly with new options like second generation proteasome inhibitors, immunomodulators, monoclonal antibodies, and CAR T cells, among others.
- - Due to the nature of multiple myeloma, many patients will experience multiple relapses and require various combination therapies that consider their specific resistance patterns and individual factors such as age and health conditions.
- - The NCCN Guidelines for multiple myeloma offer a structured approach to help healthcare providers make informed decisions regarding diagnosis, treatment, and monitoring for patients with relapsed/refractory multiple myeloma.
Introduction: The expansion of antiretroviral therapy (ART) eligibility could lead to earlier initiation of Human Immunodeficiency Virus (HIV) treatment and consequently reduce the risk of HIV-associated Kaposi Sarcoma (KS). We investigated the impact of changes in the Nigerian HIV treatment guidelines on KS incidence among adults enrolled in HIV care in Nigeria.
Methods: We analyzed data of adults who enrolled for HIV care from January 2006 to December 2016 at one of Nigeria's largest HIV treatment centers.
Article Synopsis
- GVHD in the GI tract is a leading cause of death after stem cell transplant, with higher Ann Arbor scores indicating worse outcomes and treatment resistance.
- A phase 2 study tested natalizumab, a drug that targets T-cells, combined with corticosteroids for patients with severe GVHD, showing that it was safe and well-tolerated.
- The results revealed no significant benefits of adding natalizumab, as patients had similar recovery and survival rates compared to those who only received corticosteroids.
Article Synopsis
- This study analyzed survival disparities in allogeneic hematopoietic stem cell transplantation (HSCT) among various racial/ethnic groups and income levels over a 72-month period.
- Results showed that non-Hispanic Black patients had the highest survival rates (75.6%), while Hispanic patients had the lowest (49.2%), indicating significant racial disparities in outcomes.
- The study suggests reviewing and addressing barriers in the transplant referral process to enhance access and diversify the patient population for HSCT.